|
|
 Previous Article | Table of Contents | Next Article 
Treatment of aplastic anemia in children with recombinant human granulocyte
colony-stimulating factor
S Kojima, M Fukuda, Y Miyajima, T Matsuyama and K Horibe
Division of Hematology/Oncology, Children's Medical Center, Japanese Red
Cross Nagoya First Hospital.
Twenty children (aged 1 to 17 years) with severe or moderate aplastic
anemia were treated with recombinant human granulocyte colony- stimulating
factor (rhG-CSF) at a dose of 400 micrograms/m2 per day administered as a
30-minute intravenous (IV) infusion daily for 2 weeks. This treatment
increased the neutrophil counts (2.7- to 28.0- fold) in 12 of the 20
patients. Increasing doses (800 or 1,200 micrograms/m2 per day) were
administered to five patients who had not responded to the initial dose,
and three showed an increase in neutrophil count. Differential counts of
bone marrow (BM) aspirates showed an increase in the myeloid/erythroid
ratio. The response was transient, however, and the neutrophil count
returned to baseline within 2 to 10 days of discontinuing treatment. No
severe toxicity attributable to rhG-CSF was observed. The results suggest
that this agent is effective in stimulating granulopoiesis in children with
aplastic anemia. Our study also indicates that rhG-CSF will be particularly
useful in managing patients with aplastic anemia complicated by bacterial
or fungal infection.
Volume 77,
Issue 5,
pp. 937-941,
03/01/1991
Copyright © 1991 by The American Society of Hematology
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
M. Teramura, A. Kimura, S. Iwase, Y. Yonemura, S. Nakao, A. Urabe, M. Omine, and H. Mizoguchi
Treatment of severe aplastic anemia with antithymocyte globulin and cyclosporin A with or without G-CSF in adults: a multicenter randomized study in Japan
Blood,
September 15, 2007;
110(6):
1756 - 1761.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Papaldo, G. Ferretti, S. Di Cosimo, D. Giannarelli, P. Marolla, M. Lopez, E. Cortesi, M. Antimi, E. Terzoli, P. Carlini, et al.
Does Granulocyte Colony-Stimulating Factor Worsen Anemia in Early Breast Cancer Patients Treated With Epirubicin and Cyclophosphamide?
J. Clin. Oncol.,
July 1, 2006;
24(19):
3048 - 3055.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. P. Maciejewski, E. M. Sloand, O. Nunez, C. Boss, and N. S. Young
Recombinant humanized anti-IL-2 receptor antibody (daclizumab) produces responses in patients with moderate aplastic anemia
Blood,
November 15, 2003;
102(10):
3584 - 3586.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Kojima, S. Hibi, Y. Kosaka, M. Yamamoto, M. Tsuchida, H. Mugishima, K. Sugita, H. Yabe, A. Ohara, and I. Tsukimoto
Immunosuppressive therapy using antithymocyte globulin, cyclosporine, and danazol with or without human granulocyte colony-stimulating factor in children with acquired aplastic anemia
Blood,
September 15, 2000;
96(6):
2049 - 2054.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Sreenan and H. Osiovich
Myeloid Colony-Stimulating Factors: Use in the Newborn
Arch Pediatr Adolesc Med,
September 1, 1999;
153(9):
984 - 988.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Ohara, S. Kojima, N. Hamajima, M. Tsuchida, S. Imashuku, S. Ohta, H. Sasaki, J. Okamura, K. Sugita, H. Kigasawa, et al.
Myelodysplastic Syndrome and Acute Myelogenous Leukemia as a Late Clonal Complication in Children With Acquired Aplastic Anemia
Blood,
August 1, 1997;
90(3):
1009 - 1013.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
